關鍵是後者，對照組數據16,120 and 16,130是什麽？ 研究選擇比較的對照組人數是10倍，而不是發病10倍吧？
這1612 例心肌炎和 1613 例心包炎，文章裏始終稱這部分為case patients；而對照組controls ，文裏從來沒提到或稱他們為patients（心肌/心包炎病患）。
We matched those cases（特指1612 例心肌炎和 1613 例心包炎）to 16,120 and 16,130 control subjects,（對照組） respectively. The characteristics of the cases and their matched controls are shown in Table 1. For both myocarditis and pericarditis, key differences between cases and controls included a higher proportion among cases of a history of myocarditis or pericarditis, of history of SARS-CoV-2 infection, and receipt of an mRNA Covid-19 vaccine. The mean age and proportion of women were lower among patients with myocarditis than those with pericarditis.
見這表，CASES與對照組比較，https://www.nature.com/articles/s41467-022-31401-5/tables/1
關鍵看表格裏最後3行。。這1612 例心肌炎和 1613 心包炎患者中有其病史並過去5年內曾住過院的，有的是感染過新冠的，他們之中打過/沒打疫苗大約各50%。
